Work

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Year: 2017

Type: article

Source: Science Translational Medicine

DOI: 10.1126/scitranslmed.aam7049

Institutions: The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, Institut de Recherches Internationales Servier (France), The Royal Melbourne Hospital

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Victorian Cancer Agency, Australian Cancer Research Foundation, National Breast Cancer Foundation, Royal Australasian College of Physicians, National Health and Medical Research Council

Awards: G1541584755, Elucidating the in vivo role of the pro-survival gene Mcl-1 in mammary gland development and breast cancer, G2268267925, The Australian Centre for Translational Breast Cancer Research, G395012438, G4086183777, Apoptosis and Stem Cells in Cancer, Deciphering tumour heterogeneity of breast cancer metastases using barcoded patient derived xenografts, G5409493048, G542769893, G5668503272, G696298272, G7683690874, G8550566643, G8996902947

OpenAlex ID: W2743418290

FWCI: 8.086

Cites: 66

Cited by: 195

Related to: 10